𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma

✍ Scribed by Wobser, M; Voigt, H; Eggert, A O; Houben, R; Kauczok, C S; Bröcker, E B; Becker, J C

Book ID
109999152
Publisher
Nature Publishing Group
Year
2007
Tongue
English
Weight
209 KB
Volume
96
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in cutaneous B-cell lymphoma:
Rituximab in cutaneous B-cell lymphoma: a report of two cases
✍ R.A. Sabroe; F.J. Child; A.J. Woolford; M.F. Spittle; R. Russell-Jones 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 416 KB

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphom

CHANGES IN Bcl-2 AND p53 EXPRESSION IN R
CHANGES IN Bcl-2 AND p53 EXPRESSION IN RECURRENT B-CELL LYMPHOMAS
✍ ILYAS, M.; KENDALL, M.; JALAL, H.; LINTON, C.; ROONEY, N. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 635 KB

The aim of this study was to investigate the changes involved in the evolution of nine cases of recurrent B-cell lymphomas. Using the polymerase chain reaction (PCR) on formalin-fixed, paraffin-embedded tissue from both the primary and the recurrent lymphoma of each case, monoclonality was demonstra

Expression of Fas and Fas ligand in cuta
Expression of Fas and Fas ligand in cutaneous B-cell lymphomas
✍ Zoi-Toli, Ourania; Meijer, Chris J. L. M.; Oudejans, Joost J.; de Vries, Els; va 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 3 views

Primary cutaneous B-cell lymphomas (CBCLs) represent a rare, but distinct group of B-cell neoplasms with a different clinical behaviour to B-cell lymphomas secondarily involving the skin. Fas-Fas ligand (Fasl) expression was investigated in a group of primary and secondary CBCLs to gain an insight i